Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer

British Journal of Cancer

Volumn 97, Issue 7, 2007, Pages 952-956

  Nonomura, N ^a   Takayama, H ^a   Nishimura, K ^a   Oka, D ^a   Nakai, Y ^a   Shiba, M ^a   Tsujimura, A ^a   Nakayama, M ^a   Aozasa, K ^a   Okuyama, A ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biopsy; Immunostaining; Mast cells; Prognostic factor; Prostate cancer

Indexed keywords

MONOCLONAL ANTIBODY; PROSTATE ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL COUNT; CELL INFILTRATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MAST CELL; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; SCORING SYSTEM; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; HUMANS; MALE; MAST CELLS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 34948881191     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603962     Document Type: Article

References (40)

1. Aydin OA, Dusmez D, Cinel L, Doruk E, Kanik A (2002) Immunohistological analysis of mast cell numbers in the intratumoral and peritumoral regions of regions of prostate carcinoma compared to benign prostatic hyperplasia. Pathol Res Pract 198: 267-271
2. Benyon RC, Bissonnette EY, Befus AD (1991) Tumor necrosis factor alpha-dependent cytotoxicity of human skin mast cells is enhanced by anti-IgE antibodies. J Immunol 147: 2253-2258
3. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL (1997) Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 99: 2691-2700
4. v, W/+, and +/+ mice. J Natl Cancer Inst 74: 671-674
5. Di Girolamo N, Indoh I, Jackson N, Wakefield D, McNeil HP, Yan W, Geczy C, Arm JP, Tedla N (2006) Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration. J Immunol 177: 2638-2650
6. Dimitriadou V, Koutsilieris M (1997) Mast cell-tumor cell interactions: for or against tumor growth and metastasis? Anticancer Res 17: 1541-1550
7. Fang CK, Wolters PJ, Steinhoff M, Bidgol A, Blount JL, Caughey GH (1999) Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-b. J Immunol 162: 5528-5535
8. Farram E, Nelson DS (1980) Mouse mast cell as antitumor effector cells. Cell Immunol 52: 294-301
9. Fisher ER, Fisher B (1965) Roles of mast cells in tumor growth. Arch Pathol 79: 185-191
10. Ghiara P, Boraschi D, Villar L, Scapigliati G, Taddei C, Taliabue A (1985) In vitro generated mast cells express natural cytotoxicity against tumor cells. Immunology 55: 317-324
11. Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64
12. Gruber BL, Marchase MJ, Kaw R (1995) Angiogenic factors stimulate mast cell migration. Blood 86: 2488-2493
13. Gupta RK (1970) Mast cell variations in prostate and urinary bladder. Arch Pathol 89: 302-305
14. Henderson WR, Chi EY, Jong EC, Klebanoff SJ (1981) Mast cell-mediated tumor cell cytotoxicity. Role of peroxidase. J Exp Med 153: 520-524
15. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT (2002) Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 167: 528-534
16. Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N (1999) High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 54: 467-472
17. Jenkins DC, Charles IG, Thompson LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S (1995) Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92: 4392-4396
18. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-771
19. Lachter J, Stein M, Lichtig C, Eidelman S, Munichor M (1995) Mast cells in colorectal neoplasias and premalignant disorders. Dis Colon Rectum 38: 290-293
20. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM (2000) Evidence that T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6: 1018-1023
21. Nakai Y, Nelson WG, DeMarzo AM (2007) The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res 67: 1378-1384
22. Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer statistics, 1996. CA Cancer J Clin 46: 5-27
23. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer Incidence in Five Continents, vol. VIII. Lyon: IARC Scientific Publ.
24. Partin AW, Kattan MW, Subong EN, Walsh PC, Wonjo KJ, Oesterling JE, Scardino PT, Pearson JD (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277: 1445-1451
25. Pound CR, Partin AW, Epstein JI, Walsh PC (1997) Prostate-specific antigen after anatomic radical retropubic prostatectomy. Urol Clin North Am 24: 395-406
26. Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A (2004) Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 34: 1660-1664
27. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Remoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes. J Exp Med 188: 1641-1650
28. Sari A, Serel TA, Candir O, Ozturk A, Kosar A (1999) Mast cell variations in tumour tissue and with histopathological grading in specimens of prostatic adenocarcinoma. BJU Int 84: 851-853
29. Schulz WA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Frizsche S, Wlazlinski A, Muller M, Lengauer T, Engers R, Florl AR, Wullich B, Rahnenfhrer J (2007) Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 6: 14, doi: 10.1186/1476-4598-6-14
30. Sobin LH, Wittekind Ch (1997) TNM classification of malignant tumors, 5th edn. New York: Wiley-Liss Inc
31. Stack MS, Johnson DA (1994) Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem 269: 9416-9419
32. Takanami I, Takeuchi K, Naruke M (2000) Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88: 2682-2692
33. Tanooka H, Kitamura Y, Sado T, Tanaka K, Nagase M, Kondo S (1982) Evidence for involvement of mast cells in tumor suppression in mice. J Natl Cancer Inst 69: 1305-1309
34. Tharp MD, Kasper C, Thiele D, Charley MR, Kennerly DA, Sullivan TJ (1989) Studies of connective tissue mast cell-mediated cytotoxicity. Invest Dermatol 93: 423-428
35. Tuna B, Yorukoglu K, Unlu M, Mungan MU, Kirkali Z (2006) Association of mast cells with microvessel density in renal cell carcinomas. Eur Urol 50: 530-534
36. Ueda T, Aozasa K, Tsujimoto M, Yoshikawa H, Kato T, Ono K, Matsumoto K (1988) Prognostic significance of mast cells in soft tissue sarcoma. Cancer 62: 2416-2419
37. Vincent AJ, Zhang J, Ostor A, Rogers PA, Affandi B, Kovacs G, Salamonsen LA (2000) Matrix metalloproteinase-1 and -3 and mast cells are present in the endometrium of women using progestin-only contraceptives. Hum Reprod 15: 123-130
38. Wise GJ, Marella VK, Talluni G, Shirazian D (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164: 722-725
39. Yano H, Kinuta M, Tateishi H, Nakano Y, Matsui S, Monden T, Okamura J, Sakai M, Okamoto S (1999) Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer 2: 26-32
40. Zhang L, Conejo Jr G, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213